HP
VRTX icon

HealthInvest Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

HealthInvest Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.5M Sell
19,131
-3,853
-17% -$1.71M 2.56% 16
2026
Q1 		$11.2M Hold
22,984
– – 3.61% 7
2025
Q4 		$10.4M Buy
22,984
+5,218
+29% +$2.25M 3.32% 9
2025
Q3 		$739K Sell
17,766
-6,562
-27% -$2.74M 2.74% 15
2025
Q2 		$10.8M Buy
24,328
+1,520
+7% +$700K 4.64% 7
2025
Q1 		$11.1M Buy
22,808
+551
+2% +$257K 4.88% 7
2024
Q4 		$7.6M Buy
22,257
+5,264
+31% +$2.44M 3.6% 10
2024
Q3 		$7.9M Buy
16,993
+1,898
+13% +$912K 3.71% 10
2024
Q2 		$7.08M Buy
15,095
+3,800
+34% +$1.65M 4.31% 8
2024
Q1 		$4.72M Buy
11,295
+2,165
+24% +$915K 2.87% 14
2023
Q4 		$3.71M Buy
+9,130
New +$3.37M 2.91% 17
2022
Q4 		$62.4K Buy
+216
New +$65.8K 0.12% 18
2021
Q3 		– Sell
-52,000
Closed -$10.5M – 19
2021
Q2 		$10.5M Buy
52,000
+17,000
+49% +$3.56M 9.94% 3
2021
Q1 		$7.52M Buy
+35,000
New +$7.69M 5.99% 7

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HealthInvest Partners's VRTX Position: Q2 2026 in Review

HealthInvest Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 17% in Q2 2026, selling an estimated $1.71M and leaving 19,131 shares worth $9.5M. The position accounts for 2.56% of the portfolio, ranked #16.

HealthInvest Partners first reported a position in VRTX in Q1 2021 and has held it in 14 quarters since. The position peaked at $11.2M in Q1 2026. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • HealthInvest Partners held 19,131 shares of Vertex Pharmaceuticals worth $9.5M as of Q2 2026.
  • HealthInvest Partners sold 3,853 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.71M.
  • Vertex Pharmaceuticals made up 2.56% of HealthInvest Partners's portfolio in Q2 2026, its #16 holding.
  • HealthInvest Partners first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
  • HealthInvest Partners's Vertex Pharmaceuticals position peaked at $11.2M in Q1 2026.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on HealthInvest Partners's 13F filing for Q2 2026, filed 24 Jul 2026.